{
  "description": "Demo of TrialMatchAI turning technical trial criteria into a patient\u2011friendly portal message.",
  "messages": [
    {
      "role": "system",
      "content": "You are TrialMatchAI, an AI\u2011enhanced clinical trial recruiter. You can parse eligibility text, query EMR records, and send secure messages to patients while keeping audit logs."
    },
    {
      "role": "user",
      "content": "We have a new phase III trial for metastatic non\u2011small cell lung cancer (NSCLC) testing drug XYZ. The inclusion criteria are: adults 18\u201175, confirmed stage IV NSCLC, EGFR wild\u2011type, ECOG \u22641, no prior immunotherapy, measurable disease per RECIST 1.1. Exclusion: active brain mets, uncontrolled heart disease, pregnancy. Please translate this into a patient\u2011friendly message we can send via the portal."
    },
    {
      "role": "assistant",
      "content": "Parsing the eligibility criteria into a structured format...",
      "tool_calls": [
        {
          "id": "eligibility_parser_1a2b3c",
          "name": "eligibility_parser",
          "arguments": {
            "eligibility_text": "Inclusion: adults 18\u201175, confirmed stage IV NSCLC, EGFR wild\u2011type, ECOG \u22641, no prior immunotherapy, measurable disease per RECIST 1.1. Exclusion: active brain mets, uncontrolled heart disease, pregnancy."
          }
        }
      ]
    },
    {
      "role": "tool",
      "tool_call_id": "eligibility_parser_1a2b3c",
      "content": "{\n  \"inclusion\": {\n    \"age_min\": 18,\n    \"age_max\": 75,\n    \"diagnosis\": \"metastatic non\u2011small cell lung cancer\",\n    \"stage\": \"IV\",\n    \"EGFR_status\": \"wild-type\",\n    \"ECOG_max\": 1,\n    \"no_prior_immunotherapy\": true,\n    \"measurable_disease\": true\n  },\n  \"exclusion\": {\n    \"active_brain_metastases\": true,\n    \"uncontrolled_heart_disease\": true,\n    \"pregnancy\": true\n  }\n}"
    },
    {
      "role": "assistant",
      "content": "Here is a patient\u2011friendly version you can copy\u2011paste into the secure portal message:\n\n**Subject:** New Clinical Trial for Lung Cancer Treatment (Drug XYZ)\n\n**Message:**\n\n```\nHi [Patient Name],\n\nWe are excited to let you know about a new clinical trial that may be a good match for you. The study is testing a new medicine called **Drug XYZ** for people with advanced lung cancer that has spread to other parts of the body.\n\n**Who can join?**\n- You are between **18 and 75 years old**.\n- Your lung cancer is confirmed to be **stage\u202fIV non\u2011small cell lung cancer**.\n- Your tumor does **not** have an EGFR mutation (it is \u201cwild\u2011type\u201d).\n- You are feeling fairly well, with an **ECOG performance score of 0 or 1** (you can carry out most daily activities).\n- You have **not received immunotherapy** before.\n- Your disease can be measured with standard scans (RECIST\u202f1.1).\n\n**Who cannot join?**\n- If you have active brain metastases.\n- If you have uncontrolled heart disease.\n- If you are pregnant.\n\nIf you think you might be interested or want to learn more, please reply to this message or click the link below to schedule a short video call with our study coordinator.\n\n[Schedule a Call]\n\nThank you for considering participation in this important research that could help improve treatments for lung cancer.\n\nBest regards,\nThe Clinical Trials Team\n```",
      "tool_calls": []
    }
  ]
}